Johnson & Johnson (NYSE:JNJ) Stock Position Lifted by Flossbach Von Storch SE

Flossbach Von Storch SE raised its position in Johnson & Johnson (NYSE:JNJ) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,529,296 shares of the company’s stock after buying an additional 28,814 shares during the quarter. Johnson & Johnson comprises about 3.8% of Flossbach Von Storch SE’s holdings, making the stock its 7th largest position. Flossbach Von Storch SE owned about 0.27% of Johnson & Johnson worth $944,267,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Morningstar Investment Management LLC raised its stake in shares of Johnson & Johnson by 5.5% in the fourth quarter. Morningstar Investment Management LLC now owns 5,855 shares of the company’s stock valued at $847,000 after buying an additional 303 shares during the period. First Bank & Trust bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at $936,000. Hardy Reed LLC raised its stake in shares of Johnson & Johnson by 3.9% during the 4th quarter. Hardy Reed LLC now owns 12,901 shares of the company’s stock valued at $1,866,000 after purchasing an additional 488 shares during the period. Advyzon Investment Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $732,000. Finally, Handelsbanken Fonder AB raised its stake in shares of Johnson & Johnson by 2.7% during the 4th quarter. Handelsbanken Fonder AB now owns 1,541,425 shares of the company’s stock valued at $222,921,000 after purchasing an additional 39,826 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on JNJ shares. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Guggenheim boosted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Stifel Nicolaus cut their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Finally, Raymond James cut their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Up 1.7 %

JNJ stock opened at $162.35 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market cap of $390.87 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The business has a 50 day moving average of $148.93 and a 200 day moving average of $155.86.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the company earned $2.29 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.